Da Diovan elimineres biliært, fandt CHMP imidlertid også, at der skulle fastsættes en kontraindikation for patienter med alvorlige leversygdomme, og at det "ikke bør gives til patienter med stærkt nedsat leverfunktion, cirrose eller biliær obstruktion".
However, because Diovan is eliminated via the biliary route, the CHMP agreed that it should be contraindicated in patients with severe liver diseases and “ should not be administered in patients with severe hepatic impairment, cirrhosis or biliary obstruction”.